Seminars in liver disease最新文献_第2页

Advances in Extracorporeal Liver Support. 体外肝支持的研究进展。

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-06-01 Epub Date: 2026-07-29 DOI: 10.1055/a-2926-5335

Kathryn Thompson, Hima Veeramachaneni, Ram Subramanian

{"title":"Advances in Extracorporeal Liver Support.","authors":"Kathryn Thompson, Hima Veeramachaneni, Ram Subramanian","doi":"10.1055/a-2926-5335","DOIUrl":"10.1055/a-2926-5335","url":null,"abstract":"Extracorporeal liver support (ECLS) systems provide detoxification and synthetic function support for patients with acute liver failure and acute-on-chronic liver failure to achieve spontaneous recovery of hepatic function or act as a bridge to liver transplant. Artificial ECLS (A-ECLS) systems use diffusion, convection, and adsorption to remove toxins and modulate inflammation, improving biochemical and hemodynamic parameters. Despite the development of multiple A-ECLS devices, only plasma exchange has demonstrated a survival benefit in acute liver failure, while other devices require further study. Studies in bioartificial ECLS (B-ECLS) systems have utilized human or porcine hepatocytes in the extracorporeal circuit to serve the hepatic functions of both detoxification and synthetic function, but there is insufficient evidence to support their use currently. Future studies should prioritize evaluating combination strategies that integrate A-ECLS and B-ECLS systems and should define efficacy by expanding study endpoints beyond traditional transplant-free survival endpoints to include both overall survival and transplant-related outcomes. In conclusion, current and future advances in ECLS may provide valuable therapeutic options in the management of patients with liver failure.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"171-182"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated Uric Acid and Metabolic Dysfunction-Associated Steatotic Liver Disease Progression: Where There's Smoke, is There Fire? 尿酸升高与代谢功能障碍相关的脂肪变性肝病进展：有烟必有火？

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-06-01 Epub Date: 2026-08-21 DOI: 10.1055/a-2926-5268

Eric E Kelley, Owen M Woodward, Nicholas K H Khoo

{"title":"Elevated Uric Acid and Metabolic Dysfunction-Associated Steatotic Liver Disease Progression: Where There's Smoke, is There Fire?","authors":"Eric E Kelley, Owen M Woodward, Nicholas K H Khoo","doi":"10.1055/a-2926-5268","DOIUrl":"10.1055/a-2926-5268","url":null,"abstract":"Hyperuricemia and metabolic dysfunction-associated steatotic liver disease share overlapping risk factors, yet the mechanistic contribution of uric acid remains unclear. Generation of uric acid occurs exclusively by xanthine oxidoreductase, a process intrinsically linked to electron transfer and oxidant generation, a relationship that can be viewed through electron accounting. This biochemical coupling makes it difficult to determine whether elevated uric acid drives pathology or reflects broader changes in increased redox/oxidative stress. This review highlights mechanisms of uric acid production, its dual antioxidant and pro-oxidant effects, and regulation of urate transporters. We then discuss how western dietary patterns, adiposity, and insulin resistance reshape uric acid homeostasis and intersect with pathways that promote steatosis, inflammation, and fibrogenesis. In conclusion, by framing uric acid within a liver-centered redox perspective, we consider whether elevated uric acid functions as a biomarker of metabolic stress, a contributor to disease progression, and a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"116-134"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148797920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical Guide to Best Practices in Alcohol-Associated Liver Disease. 酒精相关肝病最佳实践指南

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2026-01-08 DOI: 10.1055/a-2772-7248

Vinay Jahagirdar, Elina Stoffel, Kaanthi Rama, Alexandre Louvet, Gene Im, Juan P Arab

引用次数: 0

Endothelial Cell Therapy for the Acute and Chronic Liver Disease. 急性和慢性肝病的内皮细胞治疗

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1055/a-2841-9824

Dilnar Mahmut, Valerie Gouon-Evans

{"title":"Endothelial Cell Therapy for the Acute and Chronic Liver Disease.","authors":"Dilnar Mahmut, Valerie Gouon-Evans","doi":"10.1055/a-2841-9824","DOIUrl":"10.1055/a-2841-9824","url":null,"abstract":"Endothelial cell dysfunction and loss are key drivers of acute and chronic liver disease, underscoring a critical unmet need for liver vascular-targeted therapies. Liver sinusoidal endothelial cells are specialized endothelial cells that form a fenestrated microvascular niche regulating hepatocyte metabolism, immune homeostasis, and hepatic stellate cell activation. Repopulating this niche through transplantation of primary liver sinusoidal endothelial cells, endothelial progenitor cells, induced-pluripotent stem cell-derived liver sinusoidal endothelial cells, or engineered endothelial cells delivered within biomaterial aims to restore microvascular architecture, reestablish supportive angiocrine signaling, attenuate fibrosis, and promote liver regeneration. This review summarizes the biological rationale for endothelial cell-based therapy, compares cell sources and engineering strategies, evaluates cell delivery and engraftment approaches, and synthesizes preclinical evidence demonstrating therapeutic benefits across diverse animal models of liver injury. Finally, we highlight key translational challenges and propose future directions to accelerate the clinical development of endothelial cell-based therapies for liver disease.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"77-88"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147646430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert Practical Recommendations for Hepatocellular Carcinoma. 肝细胞癌专家实用建议。

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2026-03-25 DOI: 10.1055/a-2832-4720

Feng Su, Alejandro Torres-Hernandez, Ryan Hickey, Krishna Shanbhogue, Kristen Spencer, Karim Halazun, Augusto Villanueva

引用次数: 0

Optimizing Liver Cancer Care Through BCLC Principles. 通过BCLC原则优化肝癌治疗。

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2026-02-27 DOI: 10.1055/a-2769-7224

Gemma Iserte, Neus Llarch, Andrew M Moon, María Reig

{"title":"Optimizing Liver Cancer Care Through BCLC Principles.","authors":"Gemma Iserte, Neus Llarch, Andrew M Moon, María Reig","doi":"10.1055/a-2769-7224","DOIUrl":"10.1055/a-2769-7224","url":null,"abstract":"Hepatocellular carcinoma (HCC) care is rapidly evolving, driven by a relentless pursuit of improved patient outcomes, enhanced quality of life, and increased patient empowerment. This transformation draws inspiration from innovative concepts originating in the corporate world, notably the insights of Rita McGrath, and their application to medicine, particularly within the Barcelona Clinic Liver Cancer (BCLC) system. This review explores pivotal advancements in shared decision-making, cross-disease insights, remote monitoring and telehealth, dynamics of multidisciplinary teamwork, and patient empowerment. These innovations signify a fundamental shift in our commitment to alleviating patient distress, fostering treatment adherence, and elevating the overall patient experience. This approach not only optimizes established practices but also broadens the horizons of HCC care by transferring expertise to new domains. Advanced practice nurses (APNs) play an essential role in spearheading this transformation through patient-centered care coordination and educational initiatives, fundamentally improving the management and outcomes of HCC care within the BCLC framework. · Value-based Coordination: Dynamic scheduling, team coordination, and personalized care reduce inefficiencies, ensuring timely, patient-centered interventions.. · Empowering Nurses and Patients: Advanced practice nurses (APNs) play a central role in educating and guiding patients, boosting adherence and autonomy.. · Leveraging Technology: Tools like telemedicine and real-time alerts streamline communication, reduce hospitalizations, and optimize resource allocation.. · Scalable Solutions: The Barcelona Clinic Liver Cancer (BCLC) model offers replicable practices adaptable to broader healthcare systems..","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"23-30"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147318225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nutrition and Liver Disease. 营养与肝脏疾病。

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2025-11-28 DOI: 10.1055/a-2725-5313

Allison Franz, Henry Shay, Irina Kirpich, Craig J McClain

引用次数: 0

Hepatic Fibrosis and Liver Cancer. 肝纤维化和肝癌。

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2025-12-30 DOI: 10.1055/a-2779-4937

Aina Anton, Scott L Friedman, Bruno Cogliati

{"title":"Hepatic Fibrosis and Liver Cancer.","authors":"Aina Anton, Scott L Friedman, Bruno Cogliati","doi":"10.1055/a-2779-4937","DOIUrl":"10.1055/a-2779-4937","url":null,"abstract":"Primary liver cancer, or hepatocellular carcinoma (HCC), typically emerges in fibrotic livers where persistent inflammation and extracellular matrix (ECM) remodeling create a permissive niche for malignant transformation. Although cirrhosis remains a major risk factor, mounting data show that fibrosis itself, often in the context of metabolic dysfunction-associated steatotic liver disease (MASLD), can promote hepatocarcinogenesis even before cirrhosis develops. This review synthesizes mechanistic insights from hepatic stellate cell (HSC) biology and tumor immunology that position fibrosis as an instigator of HCC. Fibrotic remodeling increases ECM stiffness, distorts sinusoidal architecture, and promotes abnormal angiogenesis, while HSCs reprogram immune surveillance toward immune cell exclusion and immunosuppression. Aging and cellular senescence amplify these effects through a senescence-associated secretory phenotype in HSCs and hepatocytes, which fuels chronic inflammation and immune dysfunction. Metabolic crosstalk and extracellular vesicle exchange further couple stromal and epithelial programs, reinforcing stemness, therapy resistance, and metastatic fitness. In conclusion, the convergence of fibrogenic and oncogenic signaling drives HCC, uncovering actionable targets for its prevention and treatment.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"31-50"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145865436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates. 患者衍生的肝癌模型为治疗决策提供信息：最近的更新。

IF 4 3区医学

Seminars in liver disease Pub Date : 2026-03-01 Epub Date: 2026-01-14 DOI: 10.1055/a-2779-4984

Kelley Weinfurtner, Rudra Amin, Nicolas Skuli, Terence P Gade, David E Kaplan

{"title":"Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.","authors":"Kelley Weinfurtner, Rudra Amin, Nicolas Skuli, Terence P Gade, David E Kaplan","doi":"10.1055/a-2779-4984","DOIUrl":"10.1055/a-2779-4984","url":null,"abstract":"Primary liver cancer remains a global health challenge due to rising incidence, limited curative options, and poor overall survival. Poor outcomes stem from tumor heterogeneity, limited efficacy of current therapies, and comorbid chronic liver disease. Despite recent advances in immunotherapy and combination treatments, response rates remain low, and predictive biomarkers are lacking. As a result, there is an urgent need for preclinical models that capture the molecular, cellular, and immune landscape of primary liver cancer. This review discusses the strengths and limitations of patient-derived models of liver cancer, including two-dimensional patient-derived cell lines (PDCL), three-dimensional (3D) patient-derived tumor organoids (PDTOs), and patient-derived xenografts (PDXs). While PDCLs and PDTOs enable high throughput studies, they lack a representative tumor microenvironment. PDXs, including PDXs in animals with humanized immune systems, may more effectively mimic tumor-environment interactions but are costly, complex, and still contain mouse stromal cells. Ex vivo tissue culture preserves tissue structure and cell-cell interactions in an immunocompetent environment; however, short duration of viable culture limits broader application. Continued innovation in the development of multicellular three-dimensional culture systems and in vivo humanization strategies will play a critical role in enabling the development of more personalized and effective therapies for primary liver cancer.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"51-62"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-Centered Treatment of Cirrhosis. 以患者为中心的肝硬化治疗。

IF 4 3区医学

Seminars in liver disease Pub Date : 2025-12-01 Epub Date: 2025-08-18 DOI: 10.1055/a-2684-6289

Ammar Hassan, Elliot B Tapper

引用次数: 0